INCY
NASDAQ · Biotechnology
Incyte Corp
$104.40
+0.74 (+0.71%)
Financial Highlights (FY 2026)
Revenue
5.12B
Net Income
1.28B
Gross Margin
93.3%
Profit Margin
25.0%
Rev Growth
+14.8%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.3% | 93.3% | 54.9% | 54.9% |
| Operating Margin | 29.5% | 26.5% | -9.2% | -8.2% |
| Profit Margin | 25.0% | 23.8% | -9.0% | -11.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 5.12B | 4.46B | 3.83B | 4.31B |
| Gross Profit | 4.77B | 4.16B | 2.10B | 2.37B |
| Operating Income | 1.51B | 1.18B | -353,502,353 | -354,681,153 |
| Net Income | 1.28B | 1.00B | -346,012,622 | -484,699,269 |
| Gross Margin | 93.3% | 93.3% | 54.9% | 54.9% |
| Operating Margin | 29.5% | 26.5% | -9.2% | -8.2% |
| Profit Margin | 25.0% | 23.8% | -9.0% | -11.3% |
| Rev Growth | +14.8% | +14.8% | -9.6% | +14.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 65.30M | 65.30M | 7.59B | 7.36B |
| Total Equity | 9.75B | 9.75B | 11.79B | 12.61B |
| D/E Ratio | 0.01 | 0.01 | 0.64 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 1.53B | 1.27B | -409,317,505 | -495,175,433 |
| Free Cash Flow | — | — | -346,886,835 | -337,235,655 |